secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001493152-23-006927
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage appoints Jerry He as Chairman and CEO; David Green remains on Board
----------------------------------------------------------------------------

- Jerry He appointed Chairman and CEO effective March 1, 2023, replacing David Green.
- David Green to remain on Board and support transition.
- He previously served as EVP of Bright Scholar Education and CEO of Noah Education.
- Biostage is a clinical-stage biotech developing regenerative medicine for esophageal cancer.
- Company plans to begin FDA-approved clinical trial for esophageal cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223006927/0001493152-23-006927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223006927/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer